JP2018511327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511327A5 JP2018511327A5 JP2017551176A JP2017551176A JP2018511327A5 JP 2018511327 A5 JP2018511327 A5 JP 2018511327A5 JP 2017551176 A JP2017551176 A JP 2017551176A JP 2017551176 A JP2017551176 A JP 2017551176A JP 2018511327 A5 JP2018511327 A5 JP 2018511327A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- ankyrin repeat
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 55
- 102000008102 Ankyrins Human genes 0.000 claims 19
- 108010049777 Ankyrins Proteins 0.000 claims 19
- 102000023732 binding proteins Human genes 0.000 claims 18
- 108091008324 binding proteins Proteins 0.000 claims 18
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 102000057308 human HGF Human genes 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162502 | 2015-04-02 | ||
| EP15162511 | 2015-04-02 | ||
| EP15162502.7 | 2015-04-02 | ||
| EP15162511.8 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511327A JP2018511327A (ja) | 2018-04-26 |
| JP2018511327A5 true JP2018511327A5 (enExample) | 2018-11-22 |
| JP6552636B2 JP6552636B2 (ja) | 2019-07-31 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551176A Active JP6552636B2 (ja) | 2015-04-02 | 2016-04-01 | 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (enExample) |
| EP (2) | EP3277711B9 (enExample) |
| JP (1) | JP6552636B2 (enExample) |
| KR (2) | KR102427117B1 (enExample) |
| CN (1) | CN107454904A (enExample) |
| AU (3) | AU2016240220B2 (enExample) |
| BR (1) | BR112017020986A2 (enExample) |
| CA (1) | CA2979602C (enExample) |
| CL (1) | CL2017002454A1 (enExample) |
| CO (1) | CO2017009954A2 (enExample) |
| ES (1) | ES2953482T3 (enExample) |
| IL (2) | IL276944B (enExample) |
| MX (2) | MX393655B (enExample) |
| MY (1) | MY179505A (enExample) |
| NZ (1) | NZ735803A (enExample) |
| PH (1) | PH12017501792B1 (enExample) |
| RU (1) | RU2769470C2 (enExample) |
| SA (1) | SA517390092B1 (enExample) |
| SG (1) | SG11201707606RA (enExample) |
| WO (1) | WO2016156596A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| US9221892B2 (en) * | 2010-11-26 | 2015-12-29 | Molecular Partners Ag | Capping modules for designed ankyrin repeat proteins |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CN109790206A (zh) | 2016-09-22 | 2019-05-21 | 分子组合公司 | 重组结合蛋白及其用途 |
| CN110959015B (zh) * | 2017-07-12 | 2023-07-25 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
| WO2019034332A1 (en) * | 2017-08-18 | 2019-02-21 | Cambridge Enterprise Limited | MODULAR BINDING PROTEINS |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| KR20220029545A (ko) * | 2019-03-22 | 2022-03-08 | 리플렉시온 파마슈티컬스, 인크. | Vegf에 대한 d-펩티드성 화합물 |
| MX2021014649A (es) | 2019-06-04 | 2022-01-06 | Molecular Partners Ag | Dominio de repetición de anquirina diseñado con estabilidad mejorada. |
| EP3980045A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant fap binding proteins and their use |
| CA3139051A1 (en) * | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| JP2022535107A (ja) | 2019-06-04 | 2022-08-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換え４－１ｂｂ結合タンパク質及びそれらの使用 |
| CA3161319A1 (en) | 2019-12-11 | 2021-06-17 | Victor LEVITSKY | Recombinant peptide-mhc complex binding proteins and their generation and use |
| CN115003689A (zh) * | 2019-12-11 | 2022-09-02 | 分子合作伙伴股份公司 | 具有改变的表面残基的经设计的锚蛋白重复结构域 |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| BR112022023049A2 (pt) | 2020-05-14 | 2022-12-20 | Molecular Partners Ag | Proteínas multiespecíficas |
| JP2023528207A (ja) | 2020-05-14 | 2023-07-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｃｄ４０結合タンパク質及びそれらの使用 |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| CA3202358A1 (en) * | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| MX2023007067A (es) * | 2020-12-16 | 2023-08-09 | Molecular Partners Ag | Proteinas recombinantes de union a cd3 y su uso. |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| CA3211248A1 (en) | 2021-03-09 | 2022-09-15 | Nina RESCHKE | Novel darpin based cd33 engagers |
| EP4304731A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Novel darpin based multi-specific t-cell engagers |
| AU2022413461A1 (en) | 2021-12-14 | 2024-06-06 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| IL318514A (en) | 2022-08-01 | 2025-03-01 | Molecular Partners Ag | Loading and using modified re-designed websites |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251695A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd47 binding proteins and their use |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025146490A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Recombinant cd117 binding proteins and their use |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025163083A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recobminant dll3 binding proteins and their use |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| NZ581958A (en) | 2004-11-12 | 2011-01-28 | Bayer Schering Pharma Ag | Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| AU2006268780B2 (en) | 2005-07-08 | 2011-03-24 | University Of Zurich | Phage display using cotranslational translocation of fusion polypeptides |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
| RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| CN110437321A (zh) * | 2010-07-09 | 2019-11-12 | 阿菲博迪公司 | 多肽 |
| SG10201505593VA (en) * | 2010-07-19 | 2015-09-29 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| CN103459422A (zh) * | 2010-11-24 | 2013-12-18 | 葛兰素集团有限公司 | 靶向hgf的多特异性抗原结合蛋白 |
| US9221892B2 (en) | 2010-11-26 | 2015-12-29 | Molecular Partners Ag | Capping modules for designed ankyrin repeat proteins |
| EA201391607A1 (ru) | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| RU2014150224A (ru) | 2012-06-28 | 2016-08-20 | Молекьюлар Партнерс Аг | Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| JP6486908B2 (ja) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
-
2016
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 PH PH1/2017/501792A patent/PH12017501792B1/en unknown
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 MX MX2017012485A patent/MX393655B/es unknown
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active Active
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en not_active IP Right Cessation
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Ceased
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en not_active Ceased
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en not_active Ceased
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt not_active Application Discontinuation
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511327A5 (enExample) | ||
| Hong et al. | Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial | |
| JP2015522576A5 (enExample) | ||
| JP2019196365A5 (enExample) | ||
| JP2010202664A5 (enExample) | ||
| JP2017160222A5 (enExample) | ||
| JPWO2019107530A5 (enExample) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2013533858A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2012511545A5 (enExample) | ||
| JP2018503668A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| JP2014514346A5 (enExample) | ||
| JP2019525898A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2013172743A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP2017532343A5 (enExample) | ||
| JP2015505843A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2012513193A5 (enExample) |